Operator
Greetings. Welcome to ClearPoint Neuro Inc. s first-quarter financial results conference call. [Operator instructions] Please note, this conference is being recorded. Comments made on this call may include statements that are forward-looking within the meaning of the securities laws.
These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company s plans, prospects, and strategies, both preliminary and projected, and management s expectations, beliefs, estimates, or projections regarding future results of operations. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for new information or future events. For more information, please refer to the company s annual report on Form 10-K for the year ended December 31, 2020, which has been filed with the Securities and Exchange Commission, and the company s quarterly report on Form 10-Q for th
Operator
Welcome to the Q1 2021 ViewRay Incorporated earnings conference call. My name is Darryl and I ll be your operator for today s call. At this time all participants are in a listen-only mode. Later, we will conduct a question-and-answer session.
[Operator instructions] I will now turn the call over to Ashley Kluth. Ashley, you may begin.
Ashley Kluth
Senior Manager, Investor Relations
Thank you, operator. Good afternoon, everyone, and welcome to ViewRay s first-quarter 2021 financial results conference call. Joining me today are Scott Drake, our president and chief executive officer; and Zach Stassen, our chief financial officer. Earlier today, ViewRay issued a press release and presentation for today s call.
Operator
Good afternoon. Thank you for joining us today to discuss OptimizeRx Corporation s first quarter ended March 31, 2021. Speaking on the call today is OptimizeRx s chief executive officer, William Febbo; and the company s chief financial officer, Doug Baker. Miriam Paramore, the company s chief strategy officer; and chief commercial officer, Stephen Silvestro will be present for the Q&A.
Following the remarks, they will open the call for questions. Before we conclude today s call, I ll provide some important cautions regarding the forward-looking statements made by management during today s call. I d like to remind everyone that today s call is being recorded and will be made available for replay via webcast only, and instructions and today s press release are in the investor section of the company s website. Now, I turn the call over to OptimizeRx CEO, Will Febbo.